Category Blog

Your blog category

Blog

NeuDirection Limited Celebrates NMPA Clinical Trial Approval for Neu-001 to Treat Amblyopia

NeuDirection Limited is pleased to announce Neu-001 for Injection has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) on May 27, 2025. This innovative small molecule therapy is being developed for the treatment of amblyopia.…

neudirection.com
30 May 2025

Blog

CRMH Hosts International Symposium on Advancing Amblyopia Therapies in Hong Kong

The symposium “Advancing Amblyopia Care: Innovations in Clinical Trials and Multisensory Approaches in Neuroscience and Auditory Science” concluded successfully in Hong Kong on April 16,2025, with Neu-Direction playing a pivotal role in advancing the dialogue around cutting-edge therapies for amblyopia. Hosted…

neudirection.com
10 May 2025